- First conditional approval of ZYNTEGLOTM (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have ...

In Blue Bird's earnings conference call, CEO Phil Horlock noted that the company purposely sold about 600 fewer buses in fiscal 2019 versus the prior year, as it culled lower-margin models and focused ...

Bluebird Bio hasn't exactly performed well in the past five years. Despite regulatory progress, it has had to face a number of issues. Bluebird's prospects look dim even with three approved therapies.

It is hard to not get emotional when you witness the unfair reality of terrible diseases and personal stories of struggle, triumph, perseverance, and loss. So I cried — no surprise for anyone who ...

An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a ...

Gene-editing specialist Bluebird Bio (NASDAQ: BLUE) has been making plenty of noise since 2019, which is when it first earned marketing authorization for one of its breakthrough therapies, ...